Table 4 Sensitivity, specificity, and PPV of anti-citrullinated antibodies for overall JIA population and JIA subtypes
Sensitivity (%) | Specificity (%) | PPV (%) | |
|---|---|---|---|
With 95% CI | With 95% CI | With 95% CI | |
Anti-citrullinated type II collagen | |||
Antibodies (> 3.03OD) | |||
Overall (n=95) | 25.8 (17.4-36.4) | 86.2 (67.4-95.5) | 85.2 (65.4-95.1) |
Poly RF-positive (n=16) | 12.5 (2.2-39.6) | 71.2 (59.3-80.9) | 8.7 (1.5-29.5) |
Poly RF-negative (n=36) | 28.1 (14.4-47.0) | 75.4 (61.9-85.5) | 39.1 (20.5-61.2) |
Oligoarthritis (n=24) | 30.4 (14.1-53.0) | 75.8 (63.4-85.1) | 30.4 (14.1-53.0) |
Systemic-Onset (n=13) | 16.7 (2.9-49.1) | 72.7 (61.2-82.1) | 8.7 (1.5-29.5) |
Anti-citrullinated vimentin | |||
Antibodies 1–16 (> 0.79OD) | |||
Overall (n=95) | 10.9 (5.6-19.5) | 86.2 (67.4-95.5) | 71.4 (42.0-90.4) |
Poly RF-positive (n=16) | 6.3 (0.3-32.2) | 88.2 (78.2-94.1) | 10.0 (0.5-45.9) |
Poly RF-negative (n=36) | 9.1 (2.4-25.5) | 88.1 (76.5-94.7) | 30.0 (8.1-64.6) |
Oligoarthritis (n=24) | 12.5 (3.3-33.5) | 89.7 (79.3-95.4) | 30.0 (8.1-64.6) |
Systemic-Onset (n=13) | 23.1 (6.2-54.0) | 91.1 (82.0-96.1) | 30.0 (8.1-64.6) |
Anti-citrullinated vimentin | |||
Antibodies 59–74 (> 0.81OD) | |||
Overall (n=95) | 7.8 (3.5-15.9) | 89.7 (71.5-97.3) | 70.0 (35.4-91.9) |
Poly RF-positive (n=16) | 14.3 (2.5-43.8) | 93.4 (84.7-97.6) | 28.6 (5.1-69.7) |
Poly RF-negative (n=36) | 6.1 (1.1-21.6) | 91.2 (80.0-96.7) | 28.6 (5.1-69.7) |
Oligoarthritis (n=24) | 8.3 (1.5-28.5) | 92.4 (82.5-97.2) | 28.6 (5.1-69.7) |
Systemic-Onset (n=13) | 7.7 (0.4-37.9) | 92.2 (83.2-96.8) | 14.3 (0.8-58.0) |